In the phase III ECOG-ACRIN E1910 study presented at the American Society of Hematology (ASH) annual meeting, consolidation chemotherapy with blinatumomab (Blincyto) improved overall survival in ...

Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...

Please provide your email address to receive an email when new articles are posted on . “We can hopefully use these new agents in frontline therapy to increase the cure rate in adult ALL, and reduce ...

The lead investigator of the study from the Children's Oncology Group said the findings represent a new standard of care. Children with a first relapse of B-cell acute lymphoblastic leukemia (B-ALL) ...

Pediatric patients with relapsed or refractory B acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) who were treated with blinatumomab proceeded to hematopoietic cell transplant ...

Recently published in haematology journal, HemaSphere, the ALLG ALL09 ‘SUBLIME’ study, was led by Associate Professor Matthew Greenwood of the Royal North Shore Hospital in Sydney and co-ordinated ...

NEWS AT SIX. THERE IS NEW HOPE FOR CHILDREN AND ADULTS WITH LEUKEMIA, A LIFE SAVING DRUG IS CHANGING THE GAME FOR TREATING THE DISEASE. AND A KCCI INVESTIGATES REPORT. LAURA TERRELL LEARNED DOCTORS ...

In a final 5-year follow-up analysis of a phase 3 trial, blinatumomab consolidation therapy demonstrated superior event-free survival and overall survival than conventional chemotherapy among children ...

KCCI EIGHT NEWS AT TEN. DES MOINES SECOND GRADER JUST CELEBRATED A MAJOR MILESTONE. KCCI LAURA TERRELL HAS THE STORY THAT WILL NO DOUBT BRING YOU JOY. GABE FULLER IS USED TO THIS ROUTINE. BY NOW.